HCA
AZN icon

Harbour Capital Advisors’s AstraZeneca AZN Stock Holding History

Harbour Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,724
Closed -$534K – 304
2026
Q1 		$534K Buy
+2,724
New +$525K 0.1% 176
2017
Q2 		– Sell
-150
Closed -$9.34K – 270
2017
Q1 		$9.34K Buy
+150
New +$8.73K ﹤0.01% 560

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Harbour Capital Advisors's AZN Position: Q2 2026 in Review

Harbour Capital Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 2,724 shares — an estimated $534K sold.

Harbour Capital Advisors first reported a position in AZN in Q1 2017 and held it in 2 quarters. The position peaked at $534K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Harbour Capital Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Harbour Capital Advisors sold 2,724 AstraZeneca shares in Q2 2026, an estimated $534K.
  • Harbour Capital Advisors first reported a position in AstraZeneca in Q1 2017 and held it in 2 quarters.
  • Harbour Capital Advisors's AstraZeneca position peaked at $534K in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Harbour Capital Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.